A Two-part Phase I Study in Male Healthy Volunteers to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Repeated Incremental Doses of ITF2984. Part A is Double-Blind, Randomized, Subcutaneous Administration. Part B is Open Label, Continuous Infusion
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Somatostatin (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Italfarmaco
- 08 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jul 2013 New trial record